Citius Oncology (NASDAQ:CTOR) Issues Earnings Results

Citius Oncology (NASDAQ:CTOR) announced its quarterly earnings data on Friday. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01), FiscalAI reports. The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $2.50 million.

Citius Oncology Stock Performance

NASDAQ:CTOR traded up $0.08 during midday trading on Friday, hitting $0.91. The company’s stock had a trading volume of 257,395 shares, compared to its average volume of 122,617. Citius Oncology has a fifty-two week low of $0.49 and a fifty-two week high of $2.25. The firm’s 50 day moving average is $0.68 and its 200-day moving average is $0.82. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.50 and a quick ratio of 0.12. The firm has a market cap of $84.59 million, a P/E ratio of -1.94 and a beta of 3.48.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $6.00.

Institutional Trading of Citius Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in shares of Citius Oncology by 5,256.9% in the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after acquiring an additional 8,411 shares during the period. Citadel Advisors LLC purchased a new stake in Citius Oncology in the third quarter valued at $36,000. Geode Capital Management LLC grew its position in Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after purchasing an additional 36,758 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in shares of Citius Oncology during the 4th quarter valued at about $104,000. Finally, Jane Street Group LLC acquired a new position in shares of Citius Oncology in the 2nd quarter valued at about $465,000. 70.52% of the stock is currently owned by institutional investors and hedge funds.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.